Clearstead Advisors
ELTX icon

Clearstead Advisors’s Elicio Therapeutics ELTX Stock Holding History

Clearstead Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4 Buy
+2
New +$6 ﹤0.01% 3502

Other funds holding ELTX

Shah Capital Management
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
IEQ Capital
IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Leonteq Securities AG
Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Clearstead Advisors's ELTX Position: Q3 2026 in Review

Clearstead Advisors opened a new position in Elicio Therapeutics (ELTX) in Q3 2026: 2 shares worth $4. The stake represents ﹤0.01% of the portfolio and ranks #3502 among its holdings.

41 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • Clearstead Advisors held 2 shares of Elicio Therapeutics worth $4 as of Q3 2026.
  • Elicio Therapeutics was a new Clearstead Advisors position in Q3 2026.
  • Elicio Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #3502 holding.
  • 41 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.